Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020082 | 1.00 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL29074405 | 0.89 | PRCP (0.50) | HDAC3HDAC4HDAC1ALDH1A1MEN1 | |
| SCHEMBL7716515 | 0.85 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL874296 | 0.85 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7712251 | 0.83 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL20853644 | 0.83 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7712246 | 0.83 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL23116504 | 0.82 | MASP2 (0.40) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL1286910 | 0.82 | ESR1 (0.46) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL28488377 | 0.82 | LMNA (0.43) | ALDH1A1LMNAHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160886-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-05-26 | — | — | US | claimed |
| US-20210000967-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2021-01-07 | — | — | US | claimed |
| EP-2474525-B1 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| CN-101888850-A | Peptide compounds for the treatment of obesity and insulin resistance | MERCK SHARP & DOHME | 2010-11-17 | — | — | CN | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-7439228-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2008-10-21 | — | — | US | disclosed |
| CN-101277960-A | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | disclosed |
| US-20080019993-A1 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2008-01-24 | — | — | US | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | HDAC3 3434/4885HDAC4 3277/4885HDAC1 3223/4885 |
| US-20080019993-A1 | Inhibition of tumour growth | STING1, VIP, MIF | HDAC3 4221/4885HDAC4 2568/4885HDAC1 2811/4885 |
| US-20220160886-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | PAICS, PNKP, NAMPT | HDAC3 498/4885HDAC4 244/4885HDAC1 171/4885 |
| US-20210000967-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | PAICS, PNKP, NAMPT | HDAC3 498/4885HDAC4 244/4885HDAC1 171/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | HDAC3 3949/4885HDAC4 2008/4885HDAC1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.